xCELLigence RTCA eSight - 成像和阻抗
使用 RTCA eSight 軟件可輕松進(jìn)行在線數(shù)據(jù)采集和離線數(shù)據(jù)分析,符合 FDA 21 CFR Part 11 法規(guī)要求。
- RTCA Analyzers
Request a Quote
Product Details
- 將基于阻抗的無(wú)標(biāo)記 xCELLigence 實(shí)時(shí)細(xì)胞分析技術(shù)與具有紅綠藍(lán)(5x、10x 和 20x 物鏡)三色熒光的活細(xì)胞成像技術(shù)相結(jié)合,增強(qiáng)對(duì)細(xì)胞分析及其結(jié)論的信心
- 全孔成像擴(kuò)展:在進(jìn)行 QC 或定量和監(jiān)測(cè)細(xì)胞生長(zhǎng)時(shí)可觀察整個(gè)孔的情況
- 信息豐富的多重檢測(cè)在同一個(gè)孔中結(jié)合細(xì)胞阻抗和成像,所有操作都可以在培養(yǎng)箱內(nèi)完成
- 無(wú)論是 2D 還是 3D 細(xì)胞培養(yǎng),都可以通過(guò)簡(jiǎn)單的工作流程提供生理相關(guān)的數(shù)據(jù),該工作流程能夠適應(yīng)不同的實(shí)驗(yàn)方案,可同時(shí)監(jiān)測(cè)細(xì)胞活力、細(xì)胞行為、細(xì)胞功能
- 靈活的活細(xì)胞成像,支持明場(chǎng)、三個(gè)熒光通道、多種孔板形式(6、12、24、48、96 或 384 孔)和容器類(lèi)型(35 或 60 mm 培養(yǎng)皿),以及用戶自定義實(shí)驗(yàn)流程
- 分析細(xì)胞數(shù)量、增殖、細(xì)胞大小/形狀、形態(tài)變化和細(xì)胞-基底粘附強(qiáng)度的連續(xù)讀數(shù)結(jié)果
- 成像通量提升,可同時(shí)支持 5 塊 96 孔常規(guī)微孔板(所有 5 個(gè)板位),支持 3D 類(lèi)器官分析,并內(nèi)置 21 CFR Part 11 合規(guī)功能,確保實(shí)現(xiàn)安全、可審計(jì)的數(shù)據(jù)管理。
- Key Literature
-
Download Literature
Download a product brochure or data sheet
- Brochures
- English
- 23 Nov 2021
- 72.95 KB
- Application Notes
- Article Reprints
- Flyers
- Posters
- Specifications
- Technical Overviews
Videos
In Vivo DNA-launched Bispecific T Cell Engager Targeting IL-13Ra2 Controls Tumor Growth in an Animal Model of Glioblastoma Multiforme
Immuno-oncology research is changing the landscape of cancer treatment by harnessing the immune system to attack cancer cells. These immunotherapies utilize both the adaptive and innate arms of the immune system, playing a pivotal role in a host’s defense against tumors. Join the Agilent Immuno-Oncology webinar series and learn how experts in the field are making groundbreaking discoveries and taking steps towards a cancer-free world. Glioblastoma is an aggressive tumor with poor survival rates. Bispecific T cell engagers (BTEs) against different cancers are in various stages of clinical development. Toxicity resulting from cytokine release syndrome and the short half-life of BTEs, which necessitates continuous infusion—complicating delivery and increasing costs—are major challenges in the field. Here we describe the development of in vivo DNA-launched BTEs (dBTEs) with highly focused targeting of interleukin-13 receptor a2 (IL-13Ra2), a glioblastoma cell-surface target. We developed 4 BTEs targeting 2 epitopes of IL-13Ra2 and studied how heavy-light chain orientation affects BTE function. The dBTEs induced T cell activation, cytokine production, and tumor cytolysis in the presence of IL-13Ra2+ tumor cells, but we observed unique patterns of immune activation. We found a strong correlation between granzyme B secretion and dBTE-induced cytolysis of specific and nonspecific tumors. We down-selected dBTE PB01-forward based on lower cytokine induction profile and highest activation specificity. In vivo, dBTE PB01-forward demonstrated an improved half-life versus intravenous recombinant BTE delivery. In an orthotopic glioblastoma model, dBTE PB01-forward controlled tumor growth, improving animal survival, supporting the hypothesis that the blood-brain barrier does not affect the function of systemically delivered dBTE. Further study of PB01-forward for targeting glioblastoma and other IL-13Ra2+ cancers is warranted.
Armor CAR T Cells with Enhanced Potency for Cancer Immunotherapy
Explore rapid generation of non-activated CAR T cells with enhanced potency for cancer immunotherapy in this on-demand webinar from Agilent.
In process assessment of critical process parameters impacting CAR T cell potency, metabolic fitness and phenotype
Explore how Agilent's cell analysis tools enhance CAR-T cell manufacturing by providing real-time insights into immune phenotype and metabolic fitness.
Dr. Zelia Geouveia
Institut Curie
We are a laboratory working in cancer research, namely chimeric antigen receptor (CAR)-T cells targeting different antigens in the tumor. We were seeking a high throughput platform that would allow us to evaluate CAR-T cells killing in real-time. We were also interested in visualizing the killing in real time. The xCELLigence RTCA eSight was one of the technologies that could provide such information using impedance and live cell imaging (one machine, two different and precious information). When compared with other instruments that could provide imaging information only, the image quality was similar but we would not have the impedance for comparison. Thus, we decided that having both
View MoreAgilent xCELLigence RTCA 儀器助力 FDA 新批準(zhǔn)療法的效價(jià)測(cè)定程序開(kāi)發(fā)
Agilent xCELLigence 實(shí)時(shí)細(xì)胞分析 (RTCA) 技術(shù)為 Autolus Therapeutics 公司最近獲批的 CAR-T 療法 AUCATZYL 提供了精準(zhǔn)可靠的測(cè)試支持,有力推動(dòng)了效價(jià)測(cè)定程序的開(kāi)發(fā)與應(yīng)用。安捷倫通過(guò)提供準(zhǔn)確可靠的細(xì)胞分析技術(shù),幫助 Autolus 建立了強(qiáng)大的分析方法。
- 15 Jul 2025
- FAQs
-
- Instruction Sheets
- Site Preparation Checklists
- User Manuals